Skip to main content
. 2017 May 9;8(42):71782–71796. doi: 10.18632/oncotarget.17710

Figure 2. Anti-proliferation effects of compound WX-132-18B on HepG2, HeLa, A549, H460, BGC-823, MX-1, MX-1/T, and human umbilical vein endothelial cells.

Figure 2

Cells were treated with different compounds for 72 h and then assayed with the sulforhodamine B method as indicated. Values are mean±SD, n=3.